Management of Vision Decline in AMD and Glaucoma Patient
In a patient with both AMD and glaucoma experiencing vision decline from 6/40 to 6/30, immediately perform OCT imaging to determine if this represents new or worsening choroidal neovascularization (CNV) requiring anti-VEGF therapy, while simultaneously ensuring glaucoma is adequately controlled.
Immediate Diagnostic Workup
The vision decline, though seemingly modest, demands urgent evaluation because:
- Perform OCT immediately - This is the most critical test to detect subretinal or intraretinal fluid indicating active exudative AMD 1
- Amsler grid testing - Check for new metamorphopsia suggesting CNV progression 1
- Stereoscopic biomicroscopic fundus examination - Look for signs of active exudation 1
- Verify glaucoma control - Check IOP and assess optic nerve status, as uncontrolled glaucoma could contribute to vision loss
Treatment Algorithm Based on Findings
If OCT Shows Active Exudative AMD:
Initiate or intensify anti-VEGF therapy immediately with aflibercept, ranibizumab, or bevacizumab at 4-week intervals for three loading doses 1. The presence of glaucoma is NOT a contraindication to intravitreal injections, though these patients require individualized IOP monitoring 2.
Critical caveat for glaucoma patients: Monitor IOP within 12 hours post-injection, as 12.7% of patients develop transient ocular hypertension that typically resolves within 3 days with hypotensive treatment 2. Consider same-day IOP-lowering therapy if baseline glaucoma is poorly controlled.
Treatment Regimen Options:
After loading doses, choose from 1:
- Aflibercept every 8 weeks (comparable efficacy to monthly dosing after initial loading)
- Treat-and-extend protocol (adjust intervals based on treatment response)
- PRN (as-needed) based on presence/absence of fluid on OCT
If Glaucoma is Inadequately Controlled:
Optimize glaucoma therapy first, as progressive glaucomatous damage could explain vision decline. Consider surgical intervention if medical therapy fails, potentially coordinating with anti-VEGF treatment timing if both conditions require intervention 2.
Follow-Up Protocol
- Initial anti-VEGF follow-up: Every 4 weeks during loading phase 1
- Subsequent monitoring: OCT at each visit to guide treatment decisions 1
- Glaucoma monitoring: More frequent IOP checks in the first 24 hours post-injection 2
- Fluorescein angiography or OCTA: Use when clinically indicated to assess disease activity 1
Additional Management
AREDS2 supplementation: If not already prescribed, initiate high-dose antioxidants and zinc (after primary care physician review for contraindications) 1
Vision rehabilitation referral: Given baseline vision of 6/40, this patient likely qualifies for low vision services to optimize functional ability 1, 3
Patient education: Instruct on self-monitoring with Amsler grid and immediate reporting of new symptoms (metamorphopsia, scotoma, further vision loss) 1
Key Pitfall to Avoid
Do not delay treatment while trying to determine which condition (AMD vs glaucoma) is causing the vision decline. Perform OCT and IOP measurement simultaneously on the same visit - if CNV is active, even a few weeks' delay in anti-VEGF therapy can result in irreversible vision loss. The dual pathology requires parallel assessment, not sequential evaluation.